Antiendotoxin Antibodies

Abstract

Letters15 February 1995Antiendotoxin AntibodiesAlan S. CrossAlan S. CrossSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-4-199502150-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Siegel cites my concern that modulating the septic process may be a “two-edged sword,” and he defends the use of all-cause mortality as the primary end point for determining the efficacy of a potential therapeutic agent. I agree that it is not desirable to have therapies that reverse relevant endotoxin-induced physiologic variables while increasing mortality by interfering with important defense mechanisms. We have been successful in identifying situations in which antisepsis therapy is deleterious (one edge of the “two-edged sword”). The CHESS (Centocor: HA-1A Efficacy in Septic Shock), the interleukin-1Ra, and the anti-tumor necrosis factor (TNF) monoclonal ...REFERENCE1. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis. 1993; 176:112-8. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 February 1995Volume 122, Issue 4Page: 315-316KeywordsClinical trialsCytokinesEndotoxinsMonoclonal antibodiesMortalityNecrosisPopulation statisticsSepsisShockTumor necrosis factor Issue Published: 15 February 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...